Treating active psoriatic arthritis after inadequate response to DMARDs - NICE TA803
NICE TA803 - Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs
1.1 Risankizumab, alone or with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults whose disease has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them. It is recommended only if they have:
peripheral arthritis with 3 or more tender joints and 3 or more swollen joints
moderate to severe psoriasis (a body surface area of at least 3% affected by plaque psoriasis and a Psoriasis Area and Severity Index [PASI] score greater than 10)
had 2 conventional DMARDs and at least 1 biological DMARD.
Risankizumab is recommended only if the company provides it according to the commercial arrangement.